Epidemiology of sleep complaints and cardiovascular disease in the community
Description: Aims: EPICARSLEEP is a 4-year project in the primary prevention setting aiming to explore simultaneously four inter-related disease pathways (vulnerabilities) that could explain the increased risk of cardiovascular disease (CVD) in individuals with sleep complaints. Hypothesis 1 will address behavioral vulnerability by evaluating the combined contribution of lifestyle and cardiovascular risk factors using the novel concept of ideal cardiovascular health. Hypothesis 2 will address psychosocial vulnerability by exploring depression and socio economic factors at the individual and contextual levels. Hypothesis 3 will address molecular vulnerability by investigating inflammatory and non-inflammatory blood biomarkers and a large array of plasma microRNAs on baseline frozen samples. Hypothesis 4 will address vascular vulnerability and autonomic dysfunction by analyzing arterial stiffness and baroreflex sensitivity using state-of-the-art methods (high-precision carotid echotracking) and by evaluating novel heart rate parameters on Holter recordings. Methods: EPICARSLEEP combines the baseline and follow-up data of two contemporary observational community-based prospective cohorts: the Paris Prospective Study 3 (PPS3) in France, and the CoLaus/ HypnoLaus study in Switzerland. Altogether, the two studies represent 17 000 subjects (40% women) aged 50-75 (PPS3) and 35-75 (CoLaus/HypnoLaus), with a follow-up time between 9 and 13 years by 2021. A total of 338 strokes and 638 coronary events and 471 deaths are expected. In both cohorts, sleep duration, insomnia complaints and subjective daytime sleepiness have been assessed at different time points using similar standardized questionnaires (Pittsburg Sleep Quality Index and Epworth sleepiness scale). Additional common variables include: socioeconomic data at the individual and contextual level; classical CVD risk factors; depressive symptoms; inflammatory (hsCRP and IL-6) and non-inflammatory (BNP, troponins) biomarkers. Some data are cohort specific: high-precision carotid echotracking and Holter recordings for the PPS3 and polysomnographic data for the CoLaus/HypnoLaus study. Main tasks to be done include: 1) data harmonization, 2) the assessment of plasma microRNA using the largest chip available (n=752 microRNAs) in both cohorts and hs-troponin I in PPS3 and 3) heart rate parameters analysis and interpretation (PPS3) 4) completion of follow-up in both studies. Work packages (WPs): WP1 is dedicated to coordination; WP2 to data harmonization, WP3 to Holter recording analysis, WP4 to biomarker assessments, WP5 to follow-up completion and WP6 to statistical analysis and drafting manuscripts. The consortium is coordinated by JP Empana, who is Research Director at INSERM U970, principal investigator of the PPS3. EPICARSLEEP gathers experts in cardiovascular and sleep epidemiology. It includes 5 academic partners: INSERM U970, team 4 (leader JP Empana), INSERM U970, team 7 (leader: P Boutouyrie), INSERM U1016 (leader: M Andrieu), CHU de Lausanne (leader PM Vidal), and Investigation and Research centre on sleep of Lausanne (R Heinzer et JH Rubio). Expected results: we expect to 1) identify the determinants of the most common sleep complaints such as insomnia, excessive daytime sleepiness and of sleep duration; 2) assess the associations between sleep complaints and sleep duration with incident CVD; 3) identify relevant disease processes contributing to the increased risk of CVD in subjects with sleep complaints and 4) identify targets for prevention of CVD in subjects with sleep complaints. Conclusion: EPICARSLEEP will be the largest cohort worldwide in the field of sleep epidemiology. This joint collaboration including 17 000 subjects extremely well-phenotyped and followed for 9 to 13 years will provide an unique opportunity for assessing the effects of sleep duration, sleep complaints and disturbed sleep on the incidence of CVD. Budget required to ANR: 479 900 € (overhead excluded)
Funder: Agence Nationale de la Recherche
Amount: €283,900
Funding type: research
Funder scheme: AAPG2017
Start date: 2017-11-01
Investigator: Pedro MARQUES-VIDAL
Institution: Departement de Médecine Interne et Centre d'investigation et de recherche sur le sommeil
Topic: Sleep and related disorders
Subfield: Experimental and Cognitive Psychology
Field: Psychology
Domain: Social Sciences
Funded outputs count: 12
Funder award ID: ANR-17-CE36-0012
OpenAlex ID: G8300050743